JonesResearch analyst Soumit Roy downgraded Aeglea BioTherapeutics to Hold from Buy without a price target after the company terminated its classical homocystinuria program. Aeglea is evaluating strategic alternatives, will reduce its remaining workforce and will retain approximately 10 employees, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AGLE:
- Aeglea BioTherapeutics exploring strategic alternatives
- Aeglea BioTherapeutics announces interim Phase 1/2 results of pegtarviliase
- Aeglea BioTherapeutics reports Q4 revenue $200K, consensus $60K
- Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates
